Detection of Immunotoxic Gluten Peptides in Feces (CELIQK2)

University of Seville

Status: Completed

Conditions: Celiac Disease

Treatments: Other: Detection of gluten in feces

Study type: Observational

Funder types: Other

Identifiers

NCT01478867

CELIQK2

Details and patient eligibility

About

The purpose of this study is to monitor of gluten-free diet compliance in celiac patients by assessment of gliadin 33-mer equivalent epitopes in feces.

Full description

Certain immunotoxic peptides from gluten are resistant to gastrointestinal digestion and can interact with celiac patient factors to trigger immunological response. Gluten-free diet (GFD) is the only effective treatment for celiac disease (CD) and its compliance should be monitored to avoid accumulative damage. However, practical methods to monitor diet compliance and to detect the origin of an outbreak of celiac clinical symptoms are not available.

This study assesses the capacity to determine the gluten ingestion, and to monitor the GFD compliance in celiac patients by detection of gluten and gliadin 33-mer equivalent peptidic epitopes in human feces.

Enrollment: 53 patients

Sex: All

Ages: 1 to 12 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Celiac patient
• 1-12 years old
• Written informed consent

Exclusion criteria

• Known inflammatory bowel diseases
• Participation in any other studies involving investigational concomitantly or within two weeks prior to entry into the study and during the course of the study

Trial design

53 participants in 1 patient group

Celiac patients

Treatment:

Other: Detection of gluten in feces